Self-driving microscope solves previous challenges in microscopy

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

Despite major advances in immunotherapy, most patients with hepatocellular carcinoma fail to respond to current immune checkpoint inhibitors.

May 15, 2026

Vol.52 No.19

By Dan G. Duda

Drugs & Targets

FDA grants Fast Track designation to Suplexa in MSI-H CRC

FDA granted Fast Track designation to Suplexa, a differentiated, non-engineered autologous treatment, for the treatment of patients with colorectal cancer of the MSI-H phenotype.

May 15, 2026

Vol.52 No.19

Clinical Roundup

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

A blood test could map the complex ecosystem surrounding cancer cells, offering a more accurate way to predict which patients will benefit from immunotherapy, according to researchers at Mayo Clinic and Stanford Medicine. The test they developed could help guide treatment decisions across multiple cancer types and treatments.

May 08, 2026

Vol.52 No.18

Clinical Roundup

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Researchers at the University of Cincinnati Gardner Neuroscience Institute’s Brain Tumor Center have been confirmed as the first-in-the-world to achieve complete remission of a rare pituitary cancer using a novel immunotherapy treatment.

May 08, 2026

Vol.52 No.18

Clinical Roundup

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

A Mayo Clinic has developed an artificial intelligence model that can help specialists detect pancreatic cancer on routine abdominal CT scans up to three years before clinical diagnosis. It identifies subtle signs of disease before tumors are visible, when curative treatment may still be possible.

May 01, 2026

Vol.52 No.17

Clinical Trials & Tribulations

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.

March 27, 2026

Vol.52 No.12

By W. Kimryn Rathmell

Self-driving microscope solves previous challenges in microscopy

YOU MAY BE INTERESTED IN

Houston Methodist researchers identify B cells as driver of immunotherapy resistance in liver cancer

FDA grants Fast Track designation to Suplexa in MSI-H CRC

Mayo and Stanford researchers develop first blood test to map tumor “neighborhoods,” improving prediction of therapy response

University of Cincinnati achieves first-in-world remission of aggressive pituitary tumor with novel immunotherapy

Mayo Clinic AI detects pancreatic cancer up to three years before diagnosis, validation study finds

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

Renew today!

Subscriber content

Never miss an issue!

Login